Oculis Holding AG (NASDAQ:OCS) Short Interest Down 14.1% in February

Oculis Holding AG (NASDAQ:OCS) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 25,000 shares, a drop of 14.1% from the February 13th total of 29,100 shares. Based on an average trading volume of 71,300 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the company’s shares are short sold.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. abrdn plc lifted its position in Oculis by 23.0% during the 4th quarter. abrdn plc now owns 1,009,424 shares of the company’s stock worth $17,150,000 after acquiring an additional 188,871 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after purchasing an additional 1,800 shares during the period. XTX Topco Ltd acquired a new position in shares of Oculis during the fourth quarter worth $225,000. Bellevue Group AG purchased a new position in shares of Oculis in the fourth quarter valued at $170,000. Finally, Bank of America Corp DE grew its holdings in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after purchasing an additional 10,667 shares in the last quarter. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on OCS shares. HC Wainwright reduced their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Robert W. Baird increased their target price on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. Finally, Chardan Capital reissued a “buy” rating and issued a $28.00 price target on shares of Oculis in a research report on Thursday, March 13th.

Oculis Stock Performance

NASDAQ OCS opened at $19.64 on Friday. The business has a 50 day moving average price of $20.98 and a 200 day moving average price of $17.13. The company has a market capitalization of $857.52 million, a P/E ratio of -10.18 and a beta of 0.01. Oculis has a 1-year low of $10.55 and a 1-year high of $23.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. Sell-side analysts expect that Oculis will post -2.09 EPS for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.